MD, PhD, MBA
Dr. David Greene, MD, PhD, MBA, stands at the forefront of regenerative medicine and healthcare innovation, blending clinical expertise with entrepreneurial vision. As the founder and CEO of R3 Stem Cell and US Lead Network, Dr. Greene has dedicated his career to advancing patient care and empowering medical practices through advanced therapies and digital marketing excellence.
A residency and fellowship-trained orthopedic surgeon, Dr. Greene began his journey in medicine with a deep commitment to helping others. After years in clinical practice, he recognized the transformative potential of regenerative therapies and the urgent need for better patient access and education. This insight led him to establish R3 Stem Cell, now a global leader in non-surgical treatment options using stem cell and PRP therapy. Under his leadership, R3 Stem Cell has performed over 26,000 procedures across more than 45 international clinics, offering hope and healing to patients worldwide.
Dr. Greene’s entrepreneurial spirit didn’t stop at clinical innovation. He also founded US Lead Network, a healthcare internet marketing company that leverages artificial intelligence to help medical and dental practices grow their patient base efficiently and ethically. His two books on healthcare internet marketing have become essential reading for providers seeking to navigate the complexities of digital patient acquisition. Recognized as a Top 20 Expert Author by Ezines.com – ranking #15 out of over 470,000 authors and #1 in Pain Management – Dr. Greene’s thought leadership has shaped the way healthcare professionals connect with patients online.
A defining moment in Dr. Greene’s career was his decision to leave clinical practice and focus entirely on innovation and education. “I’ve never been a fan of just settling for the status quo. Innovation is a cornerstone of what makes America great,” he reflects. This philosophy has driven R3 Stem Cell’s mission to provide affordable, high-quality regenerative care and to demystify stem cell therapies through comprehensive training courses and educational content for both providers and patients.
Dr. Greene’s work has garnered international recognition, including a feature on the cover of Corporate Vision magazine, where his commitment to affordable, accessible regenerative therapies was spotlighted. His impact extends beyond business metrics – he is known for his compassionate approach, always prioritizing patient education and ethical practice.
Outside of his professional life, Dr. Greene is inspired by the words of Maya Angelou: “My mission in life is not merely to survive, but to thrive; and to do so with some passion, some compassion, some humor, and some style”. He brings this ethos to his daily work, fostering a culture of innovation, empathy, and continuous learning.
When he’s not leading global healthcare initiatives, Dr. Greene enjoys sharing insights on social media, connecting with colleagues, and pursuing personal interests that keep him grounded and inspired.
Dr. David Greene’s journey is a testament to the power of combining clinical skill, business acumen, and a heartfelt commitment to making a difference – one patient, one practice, and one innovation at a time.
All Posts
“How long will it last?” is one of the most common questions patients ask before pursuing stem cell therapy — and one of the most difficult to answer with a single number. The honest answer is: it depends. Duration of benefit varies based on the
Two of the most widely discussed treatments in regenerative medicine today are platelet-rich plasma (PRP) and exosome therapy. Patients and providers alike often ask how they compare — and whether one is better than the other. The honest answer is that they are fundamentally different
If you are exploring regenerative medicine treatments that use birth-derived tissues — such as umbilical cord stem cells or amniotic membrane — a natural first question is whether collecting these materials puts the baby or mother at risk. The answer is no. Birth tissue collection
If you have been researching regenerative medicine, you have likely come across the term “exosomes.” While stem cells have dominated the conversation for years, exosomes are rapidly emerging as one of the most scientifically compelling areas in cellular therapy and tissue regeneration. But what exactly
For families navigating an autism spectrum disorder (ASD) diagnosis, finding evidence-based treatment options can feel overwhelming. While behavioral and speech therapies remain the cornerstone of ASD management, a growing number of families are exploring regenerative medicine — specifically stem cell therapy — as a complementary
For parents considering stem cell therapy for a child with autism or cerebral palsy, one of the most pressing questions is whether sedation is safe. A recently published study offers meaningful reassurance — and it aligns with over a decade of clinical practice at R3
Years of high-impact physical activity take a profound toll on the human body. For professional skateboarder, model, and influencer Jayshawn Barrett, a lifetime of broken bones, falls, and intense training resulted in debilitating, daily joint issues. “I wake up sore, I go to sleep sore,”
For families raising a child with cerebral palsy, progress is hard-won. Therapies take years. And sometimes, even with consistent, dedicated care, gains plateau. That was Tucker’s reality. Born premature at 32 weeks and one day, he was diagnosed with periventricular leukomalacia (PVL) — white matter
For parents exploring stem cell therapy for a child with autism or cerebral palsy, sedation safety is one of the first questions that comes up. A recently published clinical study provides direct, evidence-based reassurance — finding no measurable impact on language, behavior, or cognition in
A neonatal stroke—specifically a perinatal arterial ischemic stroke—is a life-altering event that occurs in approximately 1 in 2,500 live births. These strokes often result in long-term neurological challenges, including cerebral palsy (CP), epilepsy, and significant cognitive or motor delays. Current standard care focuses on supportive
